Kiniksa Pharmaceuticals Ltd (KNSA)vsEli Lilly and Company (LLY)
KNSA
Kiniksa Pharmaceuticals Ltd
$48.42
-1.65%
HEALTHCARE · Cap: $3.99B
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 9482% more annual revenue ($72.25B vs $754.04M). LLY leads profitability with a 35.0% profit margin vs 9.7%. LLY trades at a lower P/E of 37.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
KNSA
Buy53
out of 100
Grade: C-
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.3%
Fair Value
$197.77
Current Price
$48.42
$149.35 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.5% year-over-year
Earnings expanding 145.5% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 57.0x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.48 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 53/100), backed by strong 35.0% margins and 55.5% revenue growth. KNSA offers better value entry with a 77.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is a pioneering biopharmaceutical company dedicated to addressing significant unmet medical needs through the development of novel therapies. Its lead candidate, KPL-404, is a monoclonal antibody specifically engineered to modulate immune responses, showcasing its potential in treating various autoimmune disorders. With a robust clinical pipeline and strategic partnerships bolstering its research and development efforts, Kiniksa is positioned for sustained growth in the competitive biopharmaceutical landscape. The company's steadfast commitment to innovation and reimagining treatment paradigms presents a compelling opportunity for institutional investors seeking impactful investments in transformative healthcare solutions.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?